Interní Med. 2010; 12(5): 288-294

Kombinovaná terapie hypertenze - fixní kombinace

prof.MUDr.Miroslav Souček, CSc.1, prof.MUDr.Jindřich Špinar, CSc., FESC2
1 II. interní klinika LF MU a FN u sv. Anny v Brně
2 Interní kardiologická klinika LF MU a FN Brno

Doporučení ESH/ESC z roku 2007 zdůrazňují, že monoterapie ve většině případů nevede

ke kontrole krevního tlaku, a to bez ohledu na vybranou skupinu antihypertenziv. Převážná

část pacientů k dosažení cílových hodnot vyžaduje kombinovanou léčbu, která je úspěšnější

než samotné zvýšení dávky. Je však potřeba si uvědomit i riziko nižší adherence pacienta

při nutnosti užívat více tablet. K dispozici je řada fixních kombinací, jejichž výhodou je

jednodušší užívání, a tedy vyšší pravděpodobnost adherence pacienta s léčbou. Adherence

je jistě problémem u hypertoniků, neboť onemocnění je chronické, často bez subjektivních

obtíží a dosažení cílového tlaku vyžaduje většinou kombinovanou léčbu. V posledních letech

byly publikovány nové studie týkající se kombinované léčby hypertenze, které mají důležitý

dopad na každodenní praxi a mohou pozitivně ovlivnit léčbu našich pacientů.

Keywords: hypertenze, kombinační léčba, fixní kombinace

Published: June 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Souček M, Špinar J. Kombinovaná terapie hypertenze - fixní kombinace. Interní Med. 2010;12(5):288-294.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Widimský J jr, Cífková R, Špinar J, et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Vnitř Lék 2008; 54(1): 101-118. Go to PubMed...
    2. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158. Go to original source... Go to PubMed...
    3. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trialls. Am Med 2009; 122: 290-300. Go to original source... Go to PubMed...
    4. Widimský J, et al. Hypertenze. Praha, Triton 2008; 705 s.
    5. Ferrari R. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixedcombination perindopril/amlodipine. Curr Med Res Opin 2008; 24: 3543-3557. Go to original source... Go to PubMed...
    6. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2154. Go to original source... Go to PubMed...
    7. Hannson L, Zanchetti A, Carruthers SG, et al. Effect of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized Trial. Lancet 1998; 351: 1755-1762. Go to original source... Go to PubMed...
    8. UK Prospektive Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713. Go to original source... Go to PubMed...
    9. Patel A and ADVANCE Collaborating Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829-840. Go to original source... Go to PubMed...
    10. Dluhy RG, McMahon GT. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. N Engl J Med 2008; 358: 2630-2633. Go to original source... Go to PubMed...
    11. Staessen JA, Fagard R, Thijs L, et al. for the Systolic Hypertension-Europe (Syst-Eur) Trial Investigators. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet 1997; 360: 757-764. Go to original source... Go to PubMed...
    12. Beckett NS, Peters R, Fletcher AE, et al. for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898. Go to original source... Go to PubMed...
    13. Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913. Go to original source... Go to PubMed...
    14. Jamerson KA, on behalf of the ACCOPLISH investigators. Avoiding cardiovascular events in combination therapy in patients living with systolic hypertension. American College of Cardiology Scientific Sessions; March 31, 2008; Chicago, IL.
    15. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.